Predictive factors of survival in people with Cystic fibrosis from a Spanish registry of rare diseases
e202508042
Keywords:
Cystic fibrosis, Rare disease, Survival, Epidemiology, Population-based registryAbstract
BACKGROUND // In Spain, several studies describe the population with cystic fibrosis (CF) and analyze mortality trends, but few determine factors that influence survival. The objective of this study was to analyze survival in people with CF included in a population-based registry of rare diseases and determine factors that influence it.
METHODS // An observational study was carried out in people with a confirmed diagnosis of CF until December 31, 2018 registered in the Rare Diseases Information System of the Region of Murcia (SIERrm). The Kaplan-Meier method and the log-rank test were used to estimate and compare survival curves, and the Cox proportional hazards model was used to calculate survival predictors.
RESULTS // Of 192 patients registered in SIERrm on the date of the study, 39 died, with the median age of survival being 26 years. The high-risk genotype (HR: 5.8 [95%CI: 1.97-16.94]), pancreatic insufficiency (HR: 5.4 [95%CI: 1.24-23.48]), colonization chronic by Pseudomonas aeruginosa (HR: 6.8 [95%CI: 1.21-38.54]), CF-related liver disease (HR: 5.0 (95%CI: 1.61-15.61]), and bone abnormalities (HR: 6.4 [95%CI: 1.91-21.61]) were associated with decreased survival (p<0.05). Adjusting the model for genotype, the association with high-risk genotype, CF-related liver disease, and bone changes remained (p<0.05).
CONCLUSIONS // Population registries are useful to identify patients at risk of serious disease due to their genetic and clinical characteristics, who may benefit from specific treatments and health resources that influence factors that reduce survival.
Downloads
References
De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. 2014;13(4):403-409
ECFSPR Annual Report 2018. Zolin A, Orenti A, Naehrlich L, Jung A, Van Rens J et al. 2020.
Farinha CM. CFTR and cystic fibrosis: From structure to function. 1st ed. Cham, Switzerland: Springer International Publishing; 2017.
Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic fibrosis mortality in childhood. Data from European Cystic Fibrosis Society Patient Registry. Int J Environ Res Public Health [Internet]. 2018;15(9). Disponible en: http://dx.doi.org/10.3390/ijerph15092020
Szwed A, John A, Gozdzik-Spychalska J, Czainski W, Czerniak W, Ratajczak J et al. Survival of patients with cystic fibrosis depending on mutation type and nutritional status. Adv Exp Med Biol [Internet]. 2018;1023:65-72. Disponible en: http://dx.doi.org/10.1007/5584_2017_66
Keating C, Poor AD, Liu X, Chiuzan C, Backenroth D, Zhang Y et al. Reduced survival in adult cystic fibrosis despite attenuated lung function decline. J Cyst Fibros [Internet]. 2017;16(1):78-84. Disponible en: http://dx.doi.org/10.1016/j.jcf.2016.07.012
McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW. Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol [Internet]. 2017;52(7):909-915. Disponible en: http://dx.doi.org/10.1002/ppul.23715
McKone EF, Ariti C, Jackson A, Zolin A, Carr SB, Orenti A et al. Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study. Eur Respir J [Internet]. 2021;58(3):2002288. Disponible en: http://dx.doi.org/10.1183/13993003.02288-2020
Viviani L, Bossi A, Assael BM, Italian Registry for Cystic Fibrosis Collaborative Group. Absence of a gender gap in survival. An analysis of the Italian registry for cystic fibrosis in the paediatric age. J Cyst Fibros [Internet]. 2011;10(5):313-317. Disponible en: http://dx.doi.org/10.1016/j.jcf.2011.03.007
Tridello G, Castellani C, Meneghelli I, Tamanini A, Assael BM. Early diagnosis from newborn screening maximises survival in severe cystic fibrosis. ERJ Open Res [Internet]. 2018;4(2):00109–2017. Disponible en: http://dx.doi.org/10.1183/23120541.00109-2017
George PM, Banya W, Pareek N, Bilton D, Cullinan P, Hodson ME et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ [Internet]. 2011;342(feb28 1):d1008. Disponible en: http://dx.doi.org/10.1136/bmj.d1008
Thabut G, Christie JD, Mal H, Fournier M, Brugière O, Leseche G et al. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. Am J Respir Crit Care Med [Internet]. 2013;187(12):1335-1340. Disponible en: http://dx.doi.org/10.1164/rccm.201303-0429OC
Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J [Internet]. 2007;29(3):522-526. Disponible en: http://dx.doi.org/10.1183/09031936.00099506
Burgel P-R, Bellis G, Olesen HV, Viviani L, Zolin A, Blasi F et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J [Internet]. 2015;46(1):133-141. Disponible en: http://dx.doi.org/10.1183/09031936.00196314
Hayes D Jr, Patel AV, Black SM, McCoy KS, Kirkby S, Tobias JD et al. Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. J Thorac Cardiovasc Surg [Internet]. 2015;150(3):707-13.e2. Disponible en: http://dx.doi.org/10.1016/j.jtcvs.2015.06.041
Singh H, Coffey MJ, Ooi CY. Cystic fibrosis-related liver disease is associated with increased disease burden and endocrine comorbidities. J Pediatr Gastroenterol Nutr [Internet]. 2020;70(6):796-800. Disponible en: http://dx.doi.org/10.1097/MPG.0000000000002694
O’Reilly R, Fitzpatrick P, Leen G, Elnazir B, Greally P. Severe bone demineralization is associated with higher mortality in children with cystic fibrosis. Ir Med J. 2009;102(2):47-49.
Ramalle-Gomara E, Perucha M, González M-A, Quiñones C, Andrés J, Posada M. Cystic fibrosis mortality trends in Spain among infants and young children: 1981-2004. Eur J Epidemiol [Internet]. 2008;23(8):523-529. Disponible en: http://dx.doi.org/10.1007/s10654-008-9263-1
Villaverde-Hueso A, Sánchez-Díaz G, Molina-Cabrero FJ, Gallego E, Posada de la Paz M, Alonso-Ferreira V. Mortality due to cystic fibrosis over a 36-year period in Spain: Time trends and geographic variations. Int J Environ Res Public Health [Internet]. 2019;16(1):119. Disponible en: http://dx.doi.org/10.3390/ijerph16010119
De Gracia J, Mata F, Alvarez A, Casals T, Gatner S, Vendrell M et al. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax [Internet]. 2005;60(7):558-563. Disponible en: http://dx.doi.org/10.1136/thx.2004.031153
Mira Escolano MP, Cano Candela F, Maceda Roldán LA, Sánchez Escámez A, Seiquer de la Peña C, Serrano Pinto A, Ciller Montoya P, Palomar Rodríguez JA. Fibrosis quística. Informe sobre Enfermedades Raras, IER 1901. Murcia: Consejería de Salud; 2019.
Rueda-Nieto S, Mondejar-Lopez P, Mira-Escolano M-P, Cutillas-Tolín A, Maceda-Roldán LA, Arense-Gonzalo JJ et al. Analysis of the genotypic profile and its relationship with the clinical manifestations in people with cystic fibrosis: study from a rare disease registry. Orphanet J Rare Dis [Internet]. 2022;17(1):222. Disponible en: http://dx.doi.org/10.1186/s13023-022-02373-y
Consejería de Salud RM. Decreto n. 223/2015, de 16 de septiembre, por el que se establecen los criterios de gestión y funcionamiento del Sistema de Información sobre Enfermedades Raras de la Región de Murcia [Internet]. Murciasalud.es. [citado el 16 de noviembre de 2021]. Disponible en: http://www.murciasalud.es//legislacion.php?id=331439&idsec=79
MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med [Internet]. 2014;161(4):233-241. Disponible en: http://dx.doi.org/10.7326/M13-0636
Simmonds NJ, Cullinan P, Hodson ME. Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis. Respir Med [Internet]. 2009;103(4):629-635. Disponible en: http://dx.doi.org/10.1016/j.rmed.2008.10.011
Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J [Internet]. 2015;45(3):670-679. Disponible en: http://dx.doi.org/10.1183/09031936.00119714
Desai S, Wong H, Sykes J, Stephenson AL, Singer J, Quon BS. Clinical characteristics and predictors of reduced survival for adult-diagnosed cystic fibrosis. Analysis of the Canadian CF registry. Ann Am Thorac Soc [Internet]. 2018;15(10):1177-1185. Disponible en: http://dx.doi.org/10.1513/AnnalsATS.201801-037OC
Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med [Internet]. 2010;182(5):614-626. Disponible en: http://dx.doi.org/10.1164/rccm.201001-0092OC
Dijk FN, McKay K, Barzi F, Gaskin KJ, Fitzgerald DA. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch Dis Child [Internet]. 2011;96(12):1118-1123. Disponible en: http://dx.doi.org/10.1136/archdischild-2011-300449
McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet [Internet]. 2003;361(9370):1671-1676. Disponible en: http://dx.doi.org/10.1016/s0140-6736(03)13368-5
Spanish Cystic Fibrosis Registry: Report 2018, Spanish Cystic Fibrosis Society Registry Group. Julio 2021.
Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: A population-based cohort study. Ann Intern Med [Internet]. 2017;166(8):537-546. Disponible en: http://dx.doi.org/10.7326/M16-0858
McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest [Internet]. 2006;130(5):1441-1447. Disponible en: http://dx.doi.org/10.1378/chest.130.5.1441
Durda-Masny M, Gozdzik-Spychalska J, John A, Czainski W, Strózewska W, Pawłowska N et al. The determinants of survival among adults with cystic fibrosis-a cohort study. J Physiol Anthropol [Internet]. 2021;40(1):19. Disponible en: http://dx.doi.org/10.1186/s40101-021-00269-7
Pals FH, Verkade HJ, Gulmans VAM, De Koning BAE, Koot BGP, De Meij TGJ et al. Cirrhosis associated with decreased survival and a 10-year lower median age at death of cystic fibrosis patients in the Netherlands. J Cyst Fibros [Internet]. 2019;18(3):385-389. Disponible en: http://dx.doi.org/10.1016/j.jcf.2018.11.009
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Senay Rueda Nieto, Pedro Mondejar-Lopez, María-Pilar Mira-Escolano, Ana Cutillas-Tolín, Luis Alberto Maceda-Roldán, Julián Jesús Arense-Gonzalo, Joaquín A. Palomar-Rodríguez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
